Related Experiment Video
Updated: Nov 1, 2025

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Part 2: When Should Bisphosphonates Be Used in Children with Chronic Illness Osteoporosis?
1University of Ottawa, Ottawa, Canada. Lward@cheo.on.ca.
Insights
Many children with secondary osteoporosis can recover without medication. This review guides decisions on bisphosphonate therapy by assessing recovery potential and distinguishing fragility fractures from typical childhood breaks.
Area of Science:
- Pediatric Endocrinology
- Bone Metabolism
- Pediatric Osteoporosis
Background:
- Secondary osteoporosis in children requires careful management.
- Distinguishing between primary and secondary osteoporosis is crucial for treatment decisions.
Purpose of the Study:
- To guide the decision-making process for initiating bisphosphonate therapy in children with secondary osteoporosis.
- To differentiate children who can achieve medication-unassisted recovery from those requiring intervention.
Main Methods:
- Review of natural history studies on secondary osteoporosis in children.
- Analysis of factors influencing bone recovery and vertebral reshaping.
- Evaluation of criteria for identifying bone fragility versus typical childhood fractures.
Main Results:
- Many children with secondary osteoporosis can recover fully without bisphosphonate therapy.
- Recovery can range from deterioration to significant bone mineral density (BMD) improvement and vertebral restoration.
- Vertebral reshaping is growth-dependent, necessitating timely intervention for at-risk children.
Conclusions:
- The decision to use bisphosphonates hinges on assessing recovery potential and distinguishing fragility fractures.
- Bone mineral density improvements and structural bone restitution are key indicators of recovery in pediatric osteoporosis.
- Identifying children who require bisphosphonate therapy is critical to prevent permanent deformities.
Purpose Of Review:
Part 1 of this review on secondary osteoporosis of childhood was devoted to understanding which children should undergo bone health monitoring, when to label a child with osteoporosis in this setting, and how best to monitor in order to identify early, rather than late, signs of bone fragility. In Part 2 of this review, we discuss the next critical step in deciding which children require bisphosphonate therapy. This involves distinguishing which children have the potential to undergo "medication-unassisted" recovery from secondary osteoporosis, obviating the need for bisphosphonate administration, from those who require anti-resorptive therapy in order to recover from osteoporosis.
Recent Findings:
Unlike children with primary osteoporosis such as osteogenesis imperfecta, where the potential for recovery from osteoporosis without medical therapy is limited, many children with secondary osteoporosis can undergo complete recovery in the absence of bisphosphonate intervention. Over the last decade, natural history studies have unveiled the spectrum of this recovery, which spans overt deterioration (i.e., incident vertebral and non-vertebral fractures and declines in bone mineral density (BMD)), to spectacular reclamation of BMD, and complete restoration of normal vertebral dimensions after spine fractures. The fact that reshaping of vertebral bodies following fractures is growth-dependent underscores the need to identify and treat those at risk for permanent vertebral deformity in a timely fashion. The decision to treat a child with a bisphosphonate hinges on distinguishing bone fragility from typical childhood fractures, and determining the potential for medication-unassisted recovery following an osteoporotic fragility fracture. While improvements in BMD are a well-known sign of recovery, restitution of bone structure is also a key indicator of recuperation, one that is unique to childhood, and that plays a pivotal role in the decision to intervene or not.
Related Concept Videos
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone Remodeling
Osteoclasts in Bone Remodeling
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
What is the Skeletal System?
